AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Addresses the significant threat of antimicrobial resistance.

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the ...